share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  04/19 05:32

Moomoo AI 已提取核心信息

On April 18, 2024, Adial Pharmaceuticals, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, enabling the sale of its common stock from time to time. The agreement allows for sales through a prospectus supplement and an accompanying base prospectus, which are part of a shelf registration statement declared effective by the SEC on January 24, 2024. The total market value of the common stock available for sale is approximately $4.28 million, subject to certain limitations. Sales may occur on the Nasdaq or other trading markets, and the Sales Agent may also conduct sales in privately negotiated transactions with the company's approval. Adial Pharmaceuticals will pay a 3.0% commission on gross proceeds to the Sales Agent and reimburse certain expenses. The offering will continue until all shares are sold or the agreement is terminated.
On April 18, 2024, Adial Pharmaceuticals, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, enabling the sale of its common stock from time to time. The agreement allows for sales through a prospectus supplement and an accompanying base prospectus, which are part of a shelf registration statement declared effective by the SEC on January 24, 2024. The total market value of the common stock available for sale is approximately $4.28 million, subject to certain limitations. Sales may occur on the Nasdaq or other trading markets, and the Sales Agent may also conduct sales in privately negotiated transactions with the company's approval. Adial Pharmaceuticals will pay a 3.0% commission on gross proceeds to the Sales Agent and reimburse certain expenses. The offering will continue until all shares are sold or the agreement is terminated.
2024年4月18日，Adial Pharmicals, Inc.宣布与H.C. Wainwright & Co., LLC签订了市场发行协议，允许不时出售其普通股。该协议允许通过招股说明书补充文件和随附的基本招股说明书进行销售，这些招股说明书是美国证券交易委员会于2024年1月24日宣布生效的货架注册声明的一部分。可供出售的普通股的总市值约为428万美元，但有一定的限制。销售可能发生在纳斯达克或其他交易市场，经公司批准，销售代理也可以在私下协商的交易中进行销售。Adial Pharmicals将向销售代理支付总收益的3.0％的佣金，并报销某些费用。此次发行将持续到所有股票出售或协议终止为止。
2024年4月18日，Adial Pharmicals, Inc.宣布与H.C. Wainwright & Co., LLC签订了市场发行协议，允许不时出售其普通股。该协议允许通过招股说明书补充文件和随附的基本招股说明书进行销售，这些招股说明书是美国证券交易委员会于2024年1月24日宣布生效的货架注册声明的一部分。可供出售的普通股的总市值约为428万美元，但有一定的限制。销售可能发生在纳斯达克或其他交易市场，经公司批准，销售代理也可以在私下协商的交易中进行销售。Adial Pharmicals将向销售代理支付总收益的3.0％的佣金，并报销某些费用。此次发行将持续到所有股票出售或协议终止为止。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间